Quince Therapeutics Q4 EPS $(0.21) Down From $(0.13) YoY

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.21) per share. This is a 61.54 percent decrease over losses of $(0.13) per share from the same period last year.

BenzingaApr 2 20:12

Quince Therapeutics Reported $75.1M in Cash as of December 31, 2023, Expect to Fully Fund Lead Asset, EryDex, Through Phase 3 NEAT Topline Results and Prepare for a Potential NDA Submission in 2026

Strong Cash Position Expected to Support Meaningful Clinical MilestoneReported $75.1 million in cash, cash equivalents, and short-term investments as of December 31, 2023. Quince expects its existing

BenzingaApr 1 19:08

Press Release: Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 01, 2024-- Quince Therapeutics, Inc. (Na

Dow JonesApr 1 19:00

Quince Therapeutics Launches Scientific Advisory Board

World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company's lead Phase 3 asset, new indications, and pipeline expansion Quince Therapeutics, Inc.

BusinesswireFeb 22 20:00

Quince Therapeutics Appoints Rajiv Patni to Board of Directors

TipRanksFeb 16 05:14

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to Its Board of Directors

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced

BusinesswireFeb 15 20:00